Healthcare / BiotechnologyParis
$4.78
-0.03 (-0.66%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $-6.8M · quality 42.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$94M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-1112.7%
↓Gross Margin
46.3%
↓Debt/Equity
5.97
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-49.5%
FCF CAGR
—
FCF margin
-460.8%
FCF / Net income
0.41x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.5M · net income $-16.6M · FCF $-6.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.5M | $1.5M | $9.3M | $2.1M | $11.4M |
| Net Income | $-16.6M | $-16.6M | $-9.3M | $-21.2M | $-6.9M |
| EBITDA | $-15.4M | $-15.4M | $-6.9M | $-19.4M | $-3.6M |
| EPS | -0.90 | -0.90 | -0.60 | -1.90 | -0.90 |
| Gross Margin | 46.3% | 46.3% | 88.0% | 64.4% | 83.9% |
| Operating Margin | -1068.7% | -1068.7% | -79.4% | -662.5% | -14.8% |
| Net Margin | -1124.8% | -1124.8% | -100.0% | -984.3% | -60.3% |
| Balance Sheet | |||||
| Debt/Equity | 5.97 | 5.97 | -3.83 | -1.89 | -2.56 |
| Cash Flow | |||||
| Free Cash Flow | $-6.8M | $-6.8M | $-15.8M | $-5.1M | $-15.1M |
| Returns | |||||
| ROE | -1112.7% | -1112.7% | 301.7% | 306.1% | 53.2% |
| Valuation | |||||
| P/B | 57.46 | 57.46 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | -84.2% | -84.2% | 333.5% | -81.2% | — |
| EPS Growth | -50.0% | -50.0% | 68.4% | -111.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+37.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.60 → -0.90
Residual
+37.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.